FY2026 · ended May 31, 2026 · Revenue $915.45M, +11.5% YoY · Filed Jul 28, 2026
Tilray Brands, Inc. (TLRY) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2026, which ended May 31, 2026, it reported revenue of $915.5 million and a net loss of $121.4 million. As of Aug 31, 2026 it held $224.4 million in cash and investments and $297.2 million in total debt.
Revenue (TTM)
$963.10M
+15.9% vs year-ago TTM
Net income (TTM)
$-164.22M
+92.4% vs year-ago TTM
Operating cash flow (TTM)
$-84.34M
-39.1% vs year-ago TTM
Free cash flow
$-127.52M
-112.0% vs prior year
EPS (TTM)
$-1.38
-106.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
136.20M
-87.6% vs prior year
Net cash
$-72.87M
as of Aug 31, 2026
Operating margin
-9.3%
FY 2027
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- TLRY (Nasdaq)
- Fiscal year ends
- May 31
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1731348
- Former names
- Tilray, Inc. (until Jan 10, 2022)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 May 31, 2026 |
FY 2025 May 31, 2025 |
FY 2024 May 31, 2024 |
FY 2023 May 31, 2023 |
FY 2022 May 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $915.5M | $821.3M | $788.9M | $627.1M | $628.4M |
| Operating income | -$63.0M | -$2.3B | -$174.7M | -$1.4B | -$610.4M |
| Net income | -$121.4M | -$2.2B | -$245.0M | -$1.5B | -$476.8M |
| Diluted EPS | -$1.09 | -$24.56 | -$3.30 | -$2.35 | -$0.99 |
| Operating cash flow | -$69.1M | -$94.6M | -$30.9M | $7.9M | -$177.3M |
| Free cash flow | — | -$127.5M | -$60.2M | -$12.9M | -$211.3M |
| Total assets | $2.3B | $2.1B | $4.2B | $4.3B | $5.4B |
| Total liabilities | $733.1M | $584.8M | $778.5M | $977.3M | $1.0B |
| Stockholders' equity | $1.6B | $1.5B | $3.4B | $3.3B | $4.4B |
| Cash and investments | $237.8M | $266.5M | $268.4M | $456.3M | $426.0M |
| Total debt | $180.3M | $79.0M | $83.5M | $33.7M | $221.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 8, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 8, 2026 | Oct 8, 2026 |
| ARS | Annual report to shareholders | Sep 28, 2026 | May 31, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Sep 14, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Aug 10, 2026 | Aug 4, 2026 |
| 10-K | Annual report | Jul 28, 2026 | May 31, 2026 |
All 770 Tilray Brands, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.